Literature DB >> 10739324

Tardive dyskinesia: pathophysiology and animal models.

D E Casey1.   

Abstract

Tardive dyskinesia stimulated extensive research into the mechanisms of antipsychotic drug action. A wide range of homologous, analogous, and correlational animal models have been developed to explore how typical neuroleptic drugs do and atypical antipsychotic agents do not seem to cause tardive dyskinesia. The leading hypotheses of the underlying pathophysiology of tardive dyskinesia include dopamine receptor hypersensitivity, GABA insufficiency, and/or structural abnormalities. All these hypotheses have data both for and against them. The roles of psychosis and aging must also be considered in any explanation of tardive dyskinesia. The challenge still remains of how to accurately attribute the relative contributions of each of these factors to the pathogenesis and pathophysiology of tardive dyskinesia. Fortunately, the atypical antipsychotic agents appear to greatly decrease the liability of developing tardive dyskinesia, but how this occurs remains an open and fascinating line of inquiry.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739324

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  27 in total

1.  Effects of clozapine, haloperidol, and fluoxetine on the reversal of cocaine-induced locomotor sensitization.

Authors:  Seung Keun Cha; Ung Gu Kang
Journal:  Psychiatry Investig       Date:  2014-10-20       Impact factor: 2.505

Review 2.  Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.

Authors:  Vladimir Lerner; Chanoch Miodownik
Journal:  Curr Psychiatry Rep       Date:  2011-08       Impact factor: 5.285

Review 3.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

4.  Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.

Authors:  Stanley N Caroff; Irene Hurford; Janice Lybrand; E Cabrina Campbell
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

5.  Safety and tolerability of antipsychotic polypharmacy.

Authors:  Juan A Gallego; Jimmi Nielsen; Marc De Hert; John M Kane; Christoph U Correll
Journal:  Expert Opin Drug Saf       Date:  2012-05-08       Impact factor: 4.250

6.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 7.  Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies.

Authors:  Josh Lister; José N Nobrega; Paul J Fletcher; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2014-04-22       Impact factor: 4.530

8.  Possible association between DBH 19 bp insertion/deletion polymorphism and clinical symptoms in schizophrenia with tardive dyskinesia.

Authors:  Li Hui; Mei Han; Xu Feng Huang; Min Jie Ye; Ke Zheng; Jin Cai He; Meng Han Lv; Bao Hua Zhang; Jair C Soares; Xiang Yang Zhang
Journal:  J Neural Transm (Vienna)       Date:  2014-10-22       Impact factor: 3.575

Review 9.  Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.

Authors:  Katharina Stegmayer; Sebastian Walther; Peter van Harten
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

10.  Beneficial effects of the sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 cases.

Authors:  Yakup Albayrak; Kenji Hashimoto
Journal:  Prim Care Companion CNS Disord       Date:  2012-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.